Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Technology to beat Super-bugs wins major new Funding

16.10.2007
Scientists at Biocontrol, leading the world in developing new treatments to cure serious antibiotic-resistant infections, have secured a £250,000 investment from The Capital Fund.

This is part of a funding round totalling £500,000, with the rest of the funding coming from existing Biocontrol shareholders. Established in 2002, The Capital Fund is a £50 million venture capital fund that backs fast growing small and medium-sized companies in the Greater London area, and is the largest of the nine UK regional venture capital funds.

Biocontrol has already been recognised for its innovation and expertise, recently winning a prestigious Research and Development Grant Award from the London Development Agency.

Set up in 1997, Biocontrol has been developing the clinical use of bacteriophages - literally “eaters of bacteria” - that attack dangerous infection-causing bacteria, especially in hospitals. First discovered in the early 20th century, bacteriophages, or phages, are naturally occurring viruses that attack and destroy harmful bacteria. They are highly specialised, usually attacking only specific strains of a single species of bacteria.

... more about:
»Biocontrol »Fund »Funding »phage »trials

Biocontrol’s Chief Scientific Officer, Dr David Harper, said: “The emerging crisis of resistance to antibiotics has led to renewed interest in other methods of controlling bacterial infections. We already have a product to control one type of bacterial infection in clinical trials - phages have real potential to combat many different antibiotic-resistant infections.”

Chemical antibiotics have been one of the great medical successes of the past century. But high levels of inappropriate prescribing and over-use of antibiotics in agriculture has led to a rapid and widespread development of drug-resistant bacteria. The problems posed by “superbugs”, bacteria that are immune to many regular medical antibiotics, is one that is a major concern for patients, doctors and all health professionals. Such is the ability of the bacteria to develop drug immunity that new antibiotics are in many cases becoming ineffective far more rapidly than drugs can be developed.

As phages attack only very specific bacteria, they can be a far more efficient method of bacterial control than broad-spectrum antibiotics. Dr Harper said: “Phages act like a stiletto, eliminating only the dangerous bacteria. We can identify the bacteria that are causing the disease or infection and target them with phages that will kill those bacteria and only those bacteria. This contrasts favourably with the blunt instrument approach of broad-spectrum antibiotics, which can kill a wide range of bacteria, including those that help the body. This can then leave the body open to other dangerous infections, for example, the emerging superbug C. difficile.”

Biocontrol has already successfully completed veterinary trials of its first product - a topically applied phage treatment that controls the Pseudemonas aeruginosa bacteria. Clinical trials with human patients are well underway, with positive initial results.

Dr Harper commented: “The investment from The Capital Fund will support the existing clinical trials and allow us to move forward with development of new products, including aerosol-applied treatments. There is a global need for these new medicines.”

Biocontrol’s Chairman, Dr Caroline Williams, was closely involved in the funding round. She said: “We are delighted to have secured this funding from The Capital Fund that will allow us to continue developing our product range and maintain our rapid progress. The Capital Fund has invested at a very exciting time in our development and we certainly appreciate the Fund’s willingness to support us.”

Dr Williams is also chairman of BC Capital, Biocontrol’s financial advisors who provided crucial support throughout the funding process.

Ed Simpson, Investment Manager at The Capital Fund, said: “We are delighted to be working with Biocontrol. David Harper’s team have developed some amazing products with clearly enormous potential. This investment is particularly pleasing for us as the end benefits, not just for the company and its backers but for millions of patients worldwide, could be very significant. We look forward to following Biocontrol’s progress with interest.”

Margaret Henry | alfa
Further information:
http://www.biocontrol.ltd.uk

Further reports about: Biocontrol Fund Funding phage trials

More articles from Life Sciences:

nachricht MicroRNA helps cancer evade immune system
19.09.2017 | Salk Institute

nachricht Ruby: Jacobs University scientists are collaborating in the development of a new type of chocolate
18.09.2017 | Jacobs University Bremen gGmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

Im Focus: Silencing bacteria

HZI researchers pave the way for new agents that render hospital pathogens mute

Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...

Im Focus: Artificial Enzymes for Hydrogen Conversion

Scientists from the MPI for Chemical Energy Conversion report in the first issue of the new journal JOULE.

Cell Press has just released the first issue of Joule, a new journal dedicated to sustainable energy research. In this issue James Birrell, Olaf Rüdiger,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

New quantum phenomena in graphene superlattices

19.09.2017 | Physics and Astronomy

A simple additive to improve film quality

19.09.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>